Young Chan Kim
Clinical Non-Stipendiary Lecturer; Sir Henry Wellcome Fellow; Principal Investigator; Junior Research Fellow (Wolfson); NHS Doctor
I am Sir Henry Wellcome Fellow, Principal Investigator (PI), Junior Research Fellow (JRF) at Wolfson College, and NHS doctor.
I completed a BSc degree in Biochemistry from Imperial College London and my medical degrees (BMBS, BMedSci and MRes) from the University of Nottingham. I then spent few years working in junior doctor posts before coming to Oxford to start a DPhil in Clinical Medicine. My DPhil studies focused on vaccine development against arthropod-borne viruses supported by Innovate UK funding. I was awarded highly prestigious NDM Graduate Student Prize 2020 (Overall Prize Winner) for my overall performance during my DPhil at the Nuffield Department of Medicine (NDM) and a NIHR Oxford BRC Grant to support my research as a Postdoctoral Fellow. In 2022, I was awarded the Sir Henry Wellcome Fellowship to start my independent research on vaccine development against emerging arboviruses. In 2022-2023, I have been awarded MRC HIC-VAC and MRC IAA grants to develop serological assays against typhoid and paratyphoid fever and the MLSTF grant to develop a vaccine against Chagas disease.
I am currently a Sir Henry Wellcome Fellow, a Principal Investigator (PI) at the Oxford Vaccine Group (OVG), a JRF Fellow at Wolfson College, a Lecturer in Medicine at Somerville College, and a doctor in Acute Internal Medicine in the Oxford University Hospitals NHS Foundation Trust.
López-Camacho C & Kim YC, et al. (2019). Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus. Viruses, 11 (4).
Kim YC, et al (2020). COVID-19 Vaccines: Breaking Record Times to First-in-Human Trials. NPJ Vaccines, 5, 34.
Kim YC, et al (2020). Evaluation of Chimpanzee Adenovirus and MVA Expressing TRAP and CSP from Plasmodium Cynomolgi to Prevent Malaria Relapse in Nonhuman Primates. Vaccines (Basel), 8 (3).
Folegatti P, et al (2021). A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. Nat Commun. 12, 4636 2021.
Kim YC, et al (2022). Development of novel viral vectored vaccines and virus replicon particle-based neutralization assay against Mayaro virus. Int. J. Mol. Sci. 2022, 23, 4105.